Paper Details

  1. Home
  2. Paper Details

Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.

Author: BeilkenA, BochennekK, ClaviezA, DantonelloT, DirksenU, KlingebielT, KoscielniakE, SauerbreyA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Combined treatment with topotecan and carboplatin showed a 38% objective response rate in children and adolescents with metastatic soft tissue sarcoma (STS). While effective, the toxicity profile was similar to previous monotherapeutic topotecan studies.
Paper Details　
Original Abstract of the Article :
To investigate antitumor activity and toxicity associated with combined topotecan and carboplatin treatment in children and adolescents with metastasized, untreated soft tissue sarcoma (STS).Patients (n=34) less than 21 years old and untreated, stage IV STS. Patients were treated with topotecan (1 m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0033-1341489

データ提供：米国国立医学図書館（NLM）

Topotecan and Carboplatin: A Duo Against Stage IV Soft Tissue Sarcoma

The world of cancer treatment, like a vast and unforgiving desert, constantly seeks new weapons to combat this deadly disease. This research, like a determined expedition, investigates the effectiveness of topotecan and carboplatin combination therapy in children and adolescents with metastatic soft tissue sarcoma. The researchers sought to evaluate the antitumor activity and toxicity of this combination, offering insights into its potential as a treatment option for this challenging cancer.

Topotecan and Carboplatin: A Promising Duo Against Stage IV Soft Tissue Sarcoma

The study found that this combination therapy showed promising antitumor activity, with an objective response rate of 38% in patients with stage IV soft tissue sarcoma. While this result is encouraging, further research is needed to fully understand the long-term benefits and risks of this approach. This finding is like discovering a new oasis in the desert of cancer treatment, offering a potential source of hope for patients.

Navigating the Desert of Cancer Treatment: A Guide for Parents

This research provides valuable insights into the use of topotecan and carboplatin combination therapy for children and adolescents with metastatic soft tissue sarcoma. This approach offers a promising avenue for treatment, but careful monitoring and further research are essential to ensure its safety and effectiveness. This research is like a map in the desert, guiding us towards a better understanding of this complex disease.

Dr. Camel's Conclusion

This research delves into the desert of cancer treatment, exploring the potential of a new combination therapy for stage IV soft tissue sarcoma. While the results are promising, further research is needed to fully understand its benefits and risks. This research is like a desert explorer venturing into uncharted territory, seeking new solutions to combat this challenging disease.

Date :
  1. Date Completed 2014-08-18
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

23946091

DOI: Digital Object Identifier

10.1055/s-0033-1341489

Related Literature

Article Analysis
・Side Effects of topotecan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.